UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010849
Receipt number R000012681
Scientific Title Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapy
Date of disclosure of the study information 2013/05/31
Last modified on 2015/01/28 11:16:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapy

Acronym

Study of add-on therapy with DPP-4 inhibitor in diabetic patients uncontrolled with BOT

Scientific Title

Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapy

Scientific Title:Acronym

Study of add-on therapy with DPP-4 inhibitor in diabetic patients uncontrolled with BOT

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with BOT.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of HbA1c from baseline

Key secondary outcomes

Glucose daily profile by SMBG
Frequency and severity of hypoglycemia
Frequency of other adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

patients who take the addition of DPP-4 inhibitor

Interventions/Control_2

patients who do not take the addition of DPP-4 inhibitor

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1)Type 2 diabetic patients with HbA1c(NGSP) 7.0% and more despite the target of fasting glucose level <110mg/dl by titrating insulin

2)Age: 20 to 79 years

3)No concern about the gender

4)Written informed consent are taken for the enrollment

Key exclusion criteria

1)Patients with a history of hypersensitivity to vildagliptin
2)Patients with diabetic ketoacidosis, diabetic coma and type 1 diabetes
3)Patients with severe liver dysfunction
4)Patients with severe infection, perioperative and severe trauma
5)Patients with moderate renal dysfunction or endstage renal disease on hemodialysis
6)Patients with heart failure (NYHA/New York Heart Association stage 3 or severer)
7)Pituitary insufficiency or adrenal insufficiency
8)Patienst with diarrhea, vomiting, starvation and irregular food intake
9)Patients with proliferative diabetic retinopathy
10)Patients who are pregnant, lactating, and possibly pregnant women and those planning to become pregnant

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akio Kanazawa

Organization

Juntendo University Graduate School of Medicine

Division name

Department of Metabolism & Endocrinology

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Juntendo University Graduate School of Medicine

Division name

Department of Metabolism & Endocrinology

Zip code


Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL


Homepage URL


Email



Sponsor or person

Institute

Department of Metabolism & Endocrinology
Juntendo University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 05 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 05 Month 31 Day

Date of IRB


Anticipated trial start date

2013 Year 06 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 05 Month 31 Day

Last modified on

2015 Year 01 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012681


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name